Showing results (131-140 of 396) with videos related to

Sort By:
Pageof 40
Diabetes Care|July 11, 2022
Metabolic, Intestinal, and Cardiovascular Effects of Sotagliflozin Compared With Empagliflozin in Patients With Type 2 Diabetes: A Randomized, Double-Blind StudyMaximilian G Posch, Niklas Walther, Ele Ferrannini, et al.
Diabetes Care|November 5, 2013
Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetesEle Ferrannini, Andreas Berk, Stefan Hantel, et al.
Diabetes Care|August 31, 2004
Effect of training status on regional disposal of circulating free fatty acids in the liver and skeletal muscle during physiological hyperinsulinemiaPatricia Iozzo, Teemu Takala, Vesa Oikonen, et al.
Obesity (Silver Spring, Md.)|August 11, 2006
Fasting-based estimates of insulin sensitivity in overweight and obesity: a critical appraisalJohannes B Ruige, Ilse L Mertens, Ellen Bartholomeeusen, et al.
Diabetes, Obesity & Metabolism|November 30, 2016
Effect of exenatide on postprandial glucose fluxes, lipolysis, and ß-cell function in non-diabetic, morbidly obese patientsStefania Camastra, Brenno Astiarraga, Andrea Tura, et al.
Diabetes|December 12, 2002
Prolonged in vitro exposure to autoantibodies against CD38 impairs the function and survival of human pancreatic isletsPiero Marchetti, Alessandro Antonelli, Roberto Lupi, et al.
Metabolism: Clinical and Experimental|September 28, 2011
Estimation of prehepatic insulin secretion: comparison between standardized C-peptide and insulin kinetic modelsAndrea Tura, Giovanni Pacini, Alexandra Kautzky-Willer, et al.
The Journal of Clinical Endocrinology and Metabolism|February 16, 2023
Empagliflozin and Renal Sodium-Hydrogen Exchange in Healthy SubjectsEdoardo Biancalana, Chiara Rossi, Francesco Raggi, et al.
Autoimmunity Reviews|August 31, 2014
Extra-ocular muscle cells from patients with Graves' ophthalmopathy secrete α (CXCL10) and β (CCL2) chemokines under the influence of cytokines that are modulated by PPARγAlessandro Antonelli, Silvia Martina Ferrari, Alda Corrado, et al.
Trends in Endocrinology and Metabolism: TEM|May 1, 2022
SGLT-2 inhibitors and GLP-1 receptor agonists in metabolic dysfunction-associated fatty liver diseaseJun Sung Moon, Jun Hwa Hong, Yong Jin Jung, et al.
Pageof 40